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AUTOMATED PHONE CALLS IMPROVED ADHERENCE TO INHALED 
CORTICOSTEROIDS
Feldstein A1, Vollmer W2, Rand C3
1Kaiser Permanente, Portland, OR, USA, 2Kaiser Permanente Northwest Center for Health 
Research, Portland, OR, USA, 3Johns Hopkins University, Baltimore, MD, USA
OBJECTIVES: Poor adherence to ICS among individuals with asthma is common and 
associated with increased asthma symptoms and acute health care utilization; dimin-
ished quality of life; and increased health care costs. We sought to determine if a brief, 
automated telephone intervention using speech recognition (SR) technology improved 
ICS adherence among adults with asthma. METHODS: PEANUT is an ongoing clini-
cal trial involving 14,064 members of a health maintenance organization, aged 18 
years, taking medication for the management of asthma. Participants were randomized 
to usual care (UC) or the 18-month SR arm. SR participants taking ICS receive 
monthly reﬁll reminder calls, as needed, based on dispensing data derived from the 
electronic medical record. The calls were designed using qualitative methods and 
provide educational information, explore barriers to adherence, and offer transfer to 
an automated reﬁll line as appropriate. The primary outcome is the continuous 
measure of medication adherence (CMA), a measure of medication days dispensed 
relative to total observation days. Preliminary results through the ﬁrst 8 months are 
presented. RESULTS: Of over 10,000 calls attempted so far, we successfully reached 
the target participant 45% of the time and left a voice message on an additional 40% 
of calls. CMA scores were signiﬁcantly higher for SR than UC participants (0.48 vs. 
0.45, p  0.01), with the strongest effects (a ﬁve percentage point net differential) in 
those aged 60 yrs.  CONCLUSIONS: Early results suggest a small, signiﬁcant inter-
vention effect. Because small changes in adherence on a population basis can have 
important public health beneﬁts, this study supports the potential value of SR-based 
adherence interventions for asthma and other chronic diseases.
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CLINICAL EFFECTIVENESS AND COST UTILITY OF TRUVADA,  
KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL 
NAÏVE HIV-1 INFECTED PATIENTS IN MEXICO
Rely K1, Pierre KA2, Salinas EG3
1Network on the Economic Evaluation of Healthcare Programmes and its Applications to 
Decision Making in Latin American Countries, Mexico, DF, Mexico, 2Johns Hopkins 
University, Bloomberg School of Public Health, Baltimore, MD, MD, USA, 3Hospital Infantil 
de México Federico Gómez, Mexico, DF, Mexico
OBJECTIVES: To evaluate the cost-effectiveness, from the Mexican Health Care 
System perspective, of Truvada versus Combivir and Kivexa in the treatment of anti-
retroviral naïve HIV-1 infected patients METHODS: A Markov model was developed 
to assess the incremental cost effectiveness of Truvada vs Combivir and Kivexa. Clini-
cal data was derived from published clinical trials (Study 903 and CNA30024) and 
other secondary sources to create a model of disease progression and treatment pat-
terns. Both health care and treatment costs were considered. Costs were reported in 
2008 US dollar. Costs and health outcomes were discounted at 5%. A second-order 
probabilistic Monte Carlo sensitivity analysis was conducted to assess the effects of 
parameter uncertainty on the study ﬁndings. RESULTS: The model projects an accu-
mulated discounted cost to the Mexican health care system per patient receiving the 
Truvada regimen of US$28,776 compared to US$24,605 for the Kivexa regimen and 
US$22,999 for the Combivir regimen. The accumulated discounted effect is 5.85 
QALYs per patient receiving Truvada compared to 4.89 QALYs for Kivexa and 4.81 
QALYs for Combivir. This results in an incremental cost for Truvada and Kivexa vs. 
Combivir of US$5,805 per QALY and US$19,436 per QALY respectively. Consider-
ing a willingness to pay (WTP) threshold of $US 10, 000 per QALY there is a 90% 
probability that treatment with Truvada is cost-effective relative to Combivir 
 CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use 
of Truvada in place of standard Combivir and Kivexa for treatment of HIV is likely 
to be cost effective. These conclusions are supported by conservative assumptions and 
sensitivity analyses.
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ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSISTENCE 
WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRATIVE 
CLAIMS DATABASE OF QUEBEC (CANADA)
Beland SG1, Moride Y2, Pariente A3, Tournier M3, Lebeau M4, Galbaud du Fort G5,  
Crott R6, Ducruet T4
1Université de Montreal, Montréal, QC, Canada, 2University of Montreal, Montreal, QC, 
Canada, 3Victor Segalen Bordeaux 2, Bordeaux, Bordeaux, France, 4Université de Montreal, 
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OBJECTIVES: To compare treatment persistence and incremental cost-persistence 
ratios across individual new antidepressants (SSRIs and atypical antidepressants) as 
well as the associated direct health care costs in the adult population covered by the 
public drug program of Quebec. METHODS: A retrospective cohort was conducted 
in a random sample of 13,936 adults age 18–64 years old covered by the Quebec 
public drug program and who initiated an antidepressant treatment in 2003. Persis-
tence was deﬁned as treatment duration of at least 6 months regardless of whether a 
product switch occurred. Economical impact was assessed over the ﬁrst year of treat-
ment through drug costs (antidepressants and all other drugs), medical services costs 
(psychiatric- or non-psychiatric), hospitalization costs, and total health care costs. 
Comparisons across products were conducted using the incremental cost-persistence 
ratio (ICPR). RESULTS: Treatment non-persistence ranged from 60.4% (paroxetine) 
to 65.1% (citalopram). The product associated with the highest total health care costs 
was citalopram (CDN$2653) and the lowest was venlafaxine (CND$2168). Fluvox-
amine had the lowest mean antidepressant costs (CND$215) and venlafaxine 
(CND$309) the highest; ﬂuoxetine was associated with the lowest medical services 
costs (CND$473) and hospitalization costs (CND$702), and citalopram with the 
highest for both types of costs: CND$559 for medical services and CND$970 for 
hospitalizations, respectively. Antidepressant costs, other drug costs, medical services 
costs and hospitalization costs accounted for, respectively, 10.5% (CDN$249, 95%CI: 
245–254), 33.7% (CDN$796, 95%CI: 753–839), 21.2% (CDN$501, 95%CI: 488–
514) and 34.5% (CDN$816, 95%CI: 769–862) of the total costs. The ICPR for total 
health care costs ranged from CDN$119 (ﬂuoxetine) to CDN$1,283 (paroxetine). 
CONCLUSIONS: Total costs were similar across products except for citalopram, 
which was more costly. In our ICPR analyses, paroxetine, ﬂuoxetine and venlafaxine 
appear to be the best choice compared to the other antidepressant alternatives.
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ECONOMIC BURDEN ASSOCIATED WITH DOSE-TITRATION  
AT INITIATION TO MANAGED CARE IN PATIENTS WITH  
NON-PSYCHOTIC MAJOR DEPRESSIVE DISORDER
Camacho F1, Joish VN2, Kong MC3, Sheehan D4, Balkrishnan R3
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OBJECTIVES: Although serotonin reuptake inhibitors (SSRIs) are considered cost-
effective medications to treat major depressive disorders, they are associated with sig-
niﬁcant dosage adjustments at treatment initiation. This study examined whether 
dose-titration for SSRIs at initiation was associated with increased resource utilization 
and costs. METHODS: A nationally representative cohort of individuals in the United 
States with MDD was identiﬁed in a large managed care database between January 
1, 2004 and December 31, 2006. A study-speciﬁc titration-algorithm was used to 
identify patients who had dose-titration vs. not, within the ﬁrst eight weeks of SSRI 
therapy initiation. We calculated propensity scores and identiﬁed a 1:1 matched cohort 
of titrating vs. non-titrating patients. We used univariate and multivariate statistical 
tests to compare mean therapeutic days, health care service utilization and costs 
between the two groups during the ﬁrst 8 weeks and ﬁrst 6 months of treatment initia-
tion. RESULTS: At 8 weeks, The dose-titrated cohort was estimated to have a 30% 
decrease in adjusted mean number of therapeutic days (38 vs. 54, p  0.001), a 64% 
increase in depression-related outpatient visits (1.8 vs. 1.1, p  0.001), a 74% increase 
in depression-related outpatient expenditures ($136 vs. $78, p  0.001), a 105% 
increase in depression-related psychiatrist visits (0.72 vs. 0.35, p  0.001), an increase 
in anti-depressant pharmacy costs ($138 vs. $85, p  0.001), and an increase in other 
pharmacy costs ($214 vs. $144, p-value  0.001), compared to the matched non-titrat-
ing patient cohort. Signiﬁcant differences in the same outcomes at 6 months were also 
observed. CONCLUSIONS: MDD patients who are dose-titrated with SSRIs at initia-
tion consume more medical and pharmacy resources and have more days at a sub-
therapeutic dose. Thus, antidepressants that do not require dose-titration may be 
cost-beneﬁcial to payers of health care.
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FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS  
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OBJECTIVES: To estimate the cost effectiveness and long-term combined effects of 
Posaconazole versus ﬂuconazole/itraconazole (standard azole) therapy in the prophy-
laxis against invasive fungal Infections among high-risk neutropenic patients in 
Mexico METHODS: A previously validated Markov model was used to compare the 
projected lifetime costs and effects of two theoretical groups of patients, one receiving 
Posaconazol and the other receiving standard azole. The model estimates total costs, 
numbers of IFIs, and QALY per patient in each prophylaxis group. To extrapolate 
trial results to a lifetime horizon, the model was extended with one-month Markov 
cycles in which mortality risk is speciﬁc to the underlying disease. Data on the proba-
bilities of IFI were obtained from Study Protocol PO1899. Drug costs were taken from 
average wholesale drug reports for 2008. Cost and health effects were discounted at 
5% according to the Mexican guideline. The analysis was conducted from the Mexican 
health care perspective using 2008 unit cost prices RESULTS: Our model projects an 
accumulated cost to the Mexican health care system per patient receiving the Posacon-
azol regimen of US$5634 compared to US$7463 for the standard azole regimen. The 
accumulated discounted effect is 3.13 LY or 2.25 QALYs per patient receiving 
Posaconazol, compared to 2.96 LY or 2.13 QALYs per patient receiving standard 
azole. Posaconazol remained the dominant strategy across each scenario. Probabilistic 
sensitivity analysis tested numerous assumptions about the model cost and efﬁcacy 
parameters and found that the results were robust to most changes CONCLUSIONS: 
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Posaconazole provides modest incremental beneﬁts compared with standard azole 
therapy in the prophylaxis against IFIs among high-risk neutropenic patients. Routine 
Posaconazole use appears a cost saving when the likelihood of IFIs or the cost of 
treatment medications is high.
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COSTOS DE LA ESCLEROSIS MÚLTIPLE EN COLOMBIA
Romero M1, Arango CH1, Alvis N2, Canon O3
1Synergia Consultoría y Gestión S.A, Bogotá D.C, Colombia, 2Universidad de Cartagena, 
Cartagena, Colombia, 3Fundación Salutia, Bogotá, Colombia
OBJECTIVOS: Estimar, según nivel de progresión de la enfermedad (EDSS), los costos 
de tratamiento de la Esclerosis Múltiple en Colombia, desde la perspectiva del tercero 
pagador. METODOLOGÍAS: Con base en la prevalencia de la enfermedad y desde 
la perspectiva del tercero pagador, se realizó un estudio costos de la enfermedad 
usando técnicas de estimación de doble vía: a)”top-down” para estimar costos durante 
las recaídas a partir de la revisión de registros clínicos de 304 pacientes de diferentes 
hospitales; b)”bottom-up” para estimar costos de servicios ambulatorios a partir de 
un cuestionario (Kobelt, 2006) aplicado a 137 pacientes ubicados en diferentes regio-
nes de Colombia, agrupados en 4 estadíos según EDSS. RESULTADOS: La edad 
media de los pacientes fue de 43.7 años, el 73% de los pacientes con recaídas 
 correspondió a mujeres. Las recaídas tuvieron un costo medio de $2,433,182 COP 
(U$1,237). El costo medio anual por paciente varía de acuerdo a la fase de la enfer-
medad siendo el más alto en la Fase II (EDSS 3–5.5) de $50,581,216 COP (U$25,713) 
y el más bajo para la Fase IV (EDSS 8 a 9.5) de $20,738,845 COP (U$10,543). El 
costo de los medicamentos modiﬁcadores de la enfermedad representó el 95.6% del 
costo total anual de la fase de remisión. No se encontraron diferencias de costos aso-
ciadas al género. CONCLUSIONES: La Esclerosis Múltiple en Colombia representa 
una enfermedad catastróﬁca para el sistema de salud debido al alto costo en su trata-
miento. Sus costos directos sin incluir las recaídas equivalen en promedio a 75 veces 
al costo de la prima anual del seguro de la seguridad social en salud en Colombia, 
para una persona en el año analizado (2008). Los costos varían en proporción a la 
severidad medida por EDSS.
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ECONOMIC EVALUATION OF BARIATRIC SURGERY AS TREATMENT 
FOR OBESITY AND ASSOCIATED COMORBIDITIES—ESTIMATION BY 
DISCRETE EVENT SIMULATION
Cabra HA1, Zanela OO1, Anaya P2, Rodriguez S1
1Johnson & Johnson Medical Mexico, Mexico City, Distrito Federal, Mexico, 2Fundación 
Mexicana para la Salud, Mexico City, D.F, Mexico
OBJECTIVES: Estimate the cost and return of investment (ROI) for bariatric surgery 
vs. conventional approach (diet, exercise, medications for comorbidities) as treatment 
for obesity in patients with BMI q 35 kg/m2 and at least one associated comorbidity 
in the Mexican context. METHODS: The treatment pathway of 100 patients was 
simulated by a discrete event simulation model, where bariatric surgery (interven- 
tion group) was compared to conventional treatment (control group) under the 
 institutional/hospital perspective. The considered procedures were gastric bypass (GB) 
and adjustable gastric banding (AGB), as well as bariatric surgery overall (BS), each 
independently compared and evaluated. Each created patient had unique, randomly-
assigned clinical characteristics, who was then cloned and assigned to each treatment 
group. The evaluated comorbidities were type-2 diabetes, hypertension, hypercholes-
terolemia, asthma and GERD. Data for prevalences and post-surgery resolved or 
improved comorbidity percentages were obtained from published meta-analysis. Costs 
of the pharmacologic treatment of comorbidities were taken from 2001 Seguro 
Popular reports. For the intervention group, costs of surgery and medications were 
considered, whereas only cost of medications for the control group. Twelve monthly 
surgeries were assumed in a 7- year time horizon. A 4.5% annual discount rate was 
utilized. Results are shown in years (ROI) and January 2009-adjusted Mexican pesos 
(per-patient costs) for each procedure. RESULTS: BS overall as an alternative and 
both GB and AGB as procedures were less costly than conventional treatment 
($98,200). ROI for BS, GB and AGB was 3.33, 3.16 and 5.91 years, respectively. 
Per-patient costs for BS, GB and AGB were $60,900, $56,100 and $88,600. Savings 
are due to comorbidity resolution or improvement after the surgery. CONCLUSIONS: 
Investment in bariatric surgery (GB, AGB) offsets its cost and is recouped within a 
reasonable time, thus permitting health Institutions to reduce the epidemiologic and 
economic burden obesity imposes.
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AUDITORIA BASEADA EM EVIDÊNCIAS (ABE): IMPACTO NO  
CUSTO DO TRATAMENTO QUIMIOTERÁPICO APÓS 3 ANOS  
DE IMPLANTAÇÃO
Clark LG1, Alves AF2, Castro AP2, Santos FS2, Clark O2, Engel T2, Paladini L2, Pegoretti B2, 
Faleiros E2
1Evidencias Medicas, São Paulo, Brazil, 2Evidencias Medicas, Campinas, SP, Brazil
OBJETIVOS: O custo crescente dos tratamentos quimioterápicos tem sido tópico de 
estudos em todo o mundo. Nosso objetivo foi avaliar o impacto ﬁnanceiro da implan-
tação de um sistema de ABE nos custos de quimioterapia. MÉTODOS: Num período 
de 3 meses em 2004, foram levantados os custos dos medicamentos de todos os pro-
cedimentos de quimioterapia realizados pelos quatro principais prestadores de uma 
operadora do Brasil, com 200,000 usuários. Os tratamentos foram avaliados por uma 
equipe de oncologistas auditores (OA) com extensivo treinamento em Medicina 
Baseada em Evidências (MBE) e classiﬁcados de acordo com as melhores evidências 
cientíﬁcas disponíveis como Padrão ou Experimentais. Em dezembro de 2005 foi 
implantado um sistema de auditoria de oncologia online e reforçada aos prestadores 
a necessidade da aderência aos tratamentos com embasamento cientíﬁco adequado. 
Em 2008 a extração de dados foi replicada. RESULTADOS: No período avaliado em 
2004 os prestadores realizaram 305 quimioterapias, das quais a avaliação dos OA 
considerou 230 (75.4%) padrão e 75 (24.6%) experimentais. O custo total dos 
tratamentos considerados experimentais em 2004 foi de R$ 226,282.24 ou R$ 
3,017.10 por tratamento. No mesmo período em 2008 foram realizadas 885 quimiote-
rapias, sendo o aumento causado pelo crescimento signiﬁcativo de duas das clínicas. 
Deste total os OA consideraram 828 (93.6%) padrão e 57 (6.4%) experimentais. O 
custo destes tratamentos experimentais foi R$ 379,711.25, com uma média de R$ 
6,661.60. O custo de cada tratamento experimental mais que dobrou em 4 anos 
devido à introdução de novas drogas de alto custo como os anticorpos monoclonais. 
A implantação do sistema de auditoria baseada em evidências reduziu o percentual 
de tratamentos experimentais de 24.6% para 6.4%. CONCLUSÕES: A auditoria 
baseada em evidências resulta em um controle racional dos custos com benefícios ao 
paciente, que passa a receber um tratamento fundamentado em estudos cientíﬁcos de 
boa qualidade.
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RELATIONSHIP BETWEEN ADHERENCE LEVEL TO STATINS AND 
CLINICAL ISSUES AND HEALTH CARE COSTS IN REAL LIFE  
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OBJECTIVES: To evaluate the impact of low adherence to statins on clinical issues 
and health care costs. METHODS: A cohort of 55,134 patients newly treated with 
statins was reconstructed from the RAMQ and Med-Echo databases. Subjects included 
were aged between 45 and 85, initially free of cardiovascular disease, newly treated 
with statins between 1999 and 2004 and followed-up for a minimum of 3 years. 
Adherence to statins was measured in terms of the proportion of days’ supply of 
medication dispensed over a deﬁned period, and categorized as q80% or 80%. The 
adjusted odds ratio of cardiovascular events between the two adherence groups was 
estimated using a polytomous logistic analysis. The mean costs of health care services 
were evaluated. A two-part model was applied for hospitalization costs. RESULTS: 
The mean high adherence level to statins was around to 96% during follow-up; and 
this value was at 42% for the low adherence level. The patients with low adherence 
to statins were more likely to have coronary artery disease [odds ratio (OR), 1.07; 
95% conﬁdence interval (CI), 1.01–1.13], cerebrovascular disease [OR: 1.13; 95%CI, 
1.03–1.25] and chronic heart failure [OR: 1.13; 95%CI, 1.01–1.26] within 3-year 
period of follow-up. Low adherence to statins was also associated with an increased 
risk of hospitalization by 4% (OR: 1.04; 95%CI, 1.01–1.09). Among patients who 
were hospitalized, low adherence to statins was signiﬁcantly associated with increase 
of hospitalization costs by approximately $1060/patient for a 3-year period. 
 CONCLUSIONS: Low adherence to statins was correlated with a higher risk of car-
diovascular disease and hospitalization and greater health care costs. An increased 
level of adherence to statin agents should provide a better health status for individuals 
and a net economic gain.
PODIUM SESSION III: HEALTH CARE USE & POLICY STUDIES II
HP5
PROFILE OF HTA USERS AND APPLICABILITY OF HTA REPORTS  
TO INFORM DECISIONS IN LATIN-AMERICA
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OBJECTIVES: The Institute for Clinical Effectiveness and Health Policy (IECS), an 
INAHTA member since 2005, is a major HTA agency in Latin America (LA) which 
has published over 300 HTA reports (HTAr). More than 7,200 registered users (RU) 
in IECS’s network (mainly decision-makers from Argentina -65%- and other LA 
countries -25%) have unrestricted web-based access to abstracts. One way to assess 
the impact of our HTA activities is to analyze their website use.The objective was to 
evaluate RU proﬁles, HTAr consulted and perceived impact on policy decisions. 
METHODS: Between July and November 2008, a conﬁdential self-administered 
survey was implemented to RU accessing HTAr. Data retrieved included subject 
characteristics, type of HTAr consulted and its perceived impact. RESULTS: A total 
of 1575 surveys were completed by 677 RU. While 179 HTAr were accessed, 10 were 
responsible for nearly a quarter of consultations (e.g., Bevacizumab for colorectal 
cancer, HPV vaccines, and rheumatoid arthritis treatments). Cancer-related HTAr 
were the most consulted (23%) followed by osteomuscular (15%) and cardiovascular 
(9%) topics. HTAr on drugs (48%) accounted for nearly half of the searches, followed 
by procedures (38%) and diagnostic tests (18%). Consultation reasons were institu-
tional in 58%, professional (patient-oriented) in 27% and personal (patients and rela-
